Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyAlaska Medicaid denosumab Prior Auth Coverage | Op…
    Ask Trek AI about this page
    CurrentAlaska MedicaidPolicy N/A

    Prolia®, Xgeva® (denosumab) prior authorization

    Customize your policy alerts

    Sign up for all Alaska Medicaid policy alerts

    Know when Alaska Medicaid releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization criteria for denosumab products Prolia and Xgeva covering indications, approval and denial conditions, quantity limits, and approval durations for Alaska Medicaid members.

    Policy Summary
    PayerAlaska Medicaid
    PolicyProlia®, Xgeva® (denosumab) prior authorization
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateFeb 1, 2018
    Next Review DateN/A
    Key ActionSubmit prior authorization with chart notes showing baseline labs (T-score or FRAX) and documentation of prior inadequate response or intolerance to required prior osteoporosis therapies.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Up to 6 monthsInitial approval duration
    Up to 12 monthsReauth if improved/stable
    1 syringe/6 monthsProlia quantity limit
    J0897Xgeva code

    Coverage Criteria

    Policy Summary
    PayerAlaska Medicaid
    PolicyProlia®, Xgeva® (denosumab) prior authorization
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateFeb 1, 2018
    Next Review DateN/A
    Key ActionSubmit prior authorization with chart notes showing baseline labs (T-score or FRAX) and documentation of prior inadequate response or intolerance to required prior osteoporosis therapies.
    SourceLink
    On This Page
    Coverage CriteriaCoding and LimitsPrior Authorization & Provider RequirementsBackgroundDefinitions

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    inv-01: Prolia - Initial Therapy

    Covered when ALL of the following are met

    Age and diagnosis: Patient is 18 years of age or older AND has one of the following diagnoses: decreasing bone mass in women with breast cancer; glucocorticoid-induced osteoporosis; decreasing bone mass in men with non-metastatic prostate cancer; decreasing bone mass in men with osteoporosis; or postmenopausal osteoporosis in women.age >=18
    Baseline labs/measure: Chart notes submitted with baseline labs showing one of the following: (a) a documented T-score between -1.0 and -2.5 at the lumbar spine, total hip, femoral neck, or 33% radius PLUS at least one of: current aromatase inhibitor therapy, current androgen deprivation therapy, or history of osteoporotic fracture; OR (b) FRAX 10-year probability for major osteoporotic fracture ≥20% OR hip fracture ≥3%; OR (c) T-score ≤ -2.5.T-score or FRAX thresholds
    Prior therapy: Patient has had an inadequate response to, or is unable to tolerate, at least two traditional osteoporosis treatments (oral or IV) including at least one bisphosphonate (examples: alendronate, calcitonin, ibandronate, raloxifene, risedronate, zoledronic acid).

    inv-02: Xgeva - Indication-specific Criteria

    Covered when ALL of the following are met for each indication

    Giant cell tumor of bone: Patient is 12 years of age or older AND has a diagnosis of giant cell tumor of bone AND is skeletally mature AND the tumor is unresectable or surgical resection is likely to result in severe morbidity.
    Prevention of skeletal-related events in adults: Patient is 18 years of age or older AND has a diagnosis for prevention of skeletal-related events in patients with multiple myeloma or with bone metastases from solid tumors.age >=18
    Hypercalcemia of malignancy: Patient is 18 years of age or older AND has hypercalcemia of malignancy documented by an albumin-corrected calcium >12.5 mg/dL (3.1 mmol/L) AND has had an inadequate response to, or is unable to tolerate, at least one bisphosphonate.albumin-corrected calcium >12.5 mg/dL

    Concurrent use of denosumab with another RANK ligand (RANKL) inhibitor is excluded. Requests that propose overlapping therapy with any other RANK ligand inhibitor will be denied.

    Use of Prolia or Xgeva when the specified approval criteria are not met is considered not covered / denied. If documentation does not demonstrate that all applicable criteria are satisfied, the request should be declined.

    Coding and Limits

    Denosumab product codes/limitsHCPCS | mixed
    Prolia 60 mg/1 mLProlia 60 mg/1 mL single-use prefilled syringe: 1 syringe every 6 months
    J0897Xgeva 120 mg/1.7 mL single-use vial (HCPCS) - Load: 4 vials per 28 days x 1 dose; Maintenance: 1 vial monthly
    FRAX 10-year probability
    Measure10-year probability for major osteoporotic fracture ≥20% OR 10-year probability of hip fracture ≥3% (FRAX, U.S. adapted WHO algorithm)
    Where reportedFRAX calculated using the U.S. adapted World Health Organization algorithm
    Use in Prolia criteriaAcceptable alternative to T-score for baseline fracture risk assessment when chart notes submitted
    Hypercalcemia threshold
    ThresholdAlbumin-corrected calcium >12.5 mg/dL (3.1 mmol/L)
    ContextRequired to document hypercalcemia of malignancy for Xgeva eligibility
    Prior therapy requirementHypercalcemia must be documented and patient must have had inadequate response to or intolerance of at least one bisphosphonate (as applicable)

    Prior Authorization & Provider Requirements

    Prior Authorization

    Prolia prior authorization required

    Prior authorization required for Prolia (60 mg) — submit documentation that the patient is ≥18 years old, has one of the listed qualifying diagnoses, baseline labs/measurements meeting T‑score or FRAX thresholds, and prior inadequate response or intolerance to at least two traditional osteoporosis therapies (one must be a bisphosphonate).

    • Age ≥18 years.
    • One of the specified diagnoses (e.g., postmenopausal osteoporosis, glucocorticoid‑induced osteoporosis, decreasing bone mass in men, etc.).
    • Baseline objective measure: (a) T‑score between -1.0 and -2.5 at specified sites plus qualifying risk factor, OR (b) FRAX 10‑year major osteoporotic fracture ≥20% or hip ≥3%, OR (c) T‑score ≤ -2.5.
    • Inadequate response to or intolerance of ≥2 traditional osteoporosis treatments (oral or IV), including at least one bisphosphonate.
    Prior Authorization

    Xgeva prior authorization required

    Prior authorization required for Xgeva — submit documentation of the specific indication and supporting clinical details depending on indication: unresectable giant cell tumor of bone in skeletally mature patients; prevention of skeletal‑related events in adults with bone metastases/multiple myeloma; or hypercalcemia of malignancy with albumin‑corrected calcium >12.5 mg/dL and prior bisphosphonate failure/intolerance as applicable.

    • For giant cell tumor of bone: patient ≥12 years, diagnosis of GCTB, documented skeletal maturity, and tumor unresectable or surgery likely to cause severe morbidity.
    • For prevention of skeletal‑related events: patient ≥18 years with bone metastases or multiple myeloma.
    • For hypercalcemia of malignancy: patient ≥18 years with albumin‑corrected calcium >12.5 mg/dL and inadequate response or intolerance to ≥1 bisphosphonate.
    Step Therapy

    Step therapy (Prolia; Xgeva hypercalcemia)

    Step therapy required prior to Prolia: provider must document inadequate response to or intolerance of at least two traditional osteoporosis therapies, with at least one being a bisphosphonate.

    • Traditional therapies include oral or IV treatments such as alendronate, calcitonin, ibandronate, raloxifene, risedronate, or zoledronic acid.
    • For Xgeva used for hypercalcemia of malignancy, document inadequate response to or intolerance of at least one bisphosphonate.
    Documentation Required

    Required documentation for Prolia (baseline labs/measure)

    Submit chart notes with baseline objective measures for Prolia requests: either a qualifying T‑score at specified sites with associated risk factor, a FRAX 10‑year probability meeting threshold, or a T‑score ≤ -2.5.

    • Acceptable baseline documentation: (a) T‑score between -1.0 and -2.5 at lumbar spine, total hip, femoral neck, or 33% radius plus being on aromatase inhibitor OR androgen deprivation therapy OR history of osteoporotic fracture; (b) FRAX major osteoporotic fracture ≥20% or hip ≥3%; or (c) T‑score ≤ -2.5.
    Documentation Required

    Required documentation for Xgeva

    For Xgeva requests, submit documentation of the diagnosis and skeletal maturity when for giant cell tumor of bone, and laboratory evidence when for hypercalcemia of malignancy (albumin‑corrected calcium >12.5 mg/dL); also document prior bisphosphonate failure/intolerance when applicable.

    • Giant cell tumor of bone: documentation that patient is ≥12 years and skeletally mature and that tumor is unresectable or surgery would cause severe morbidity.
    • Hypercalcemia of malignancy: albumin‑corrected calcium >12.5 mg/dL and prior inadequate response or intolerance to ≥1 bisphosphonate.
    Denial Risk

    Denial triggers and risks

    Denial will be issued if approval criteria are not met, if the patient will be taking another RANK ligand inhibitor concurrently, or if pre‑existing hypocalcemia has not been corrected with adequate calcium and vitamin D supplementation.

    • Use when approval criteria are not met results in denial.
    • Concurrent use with another RANK ligand inhibitor is a denial trigger.
    • Uncorrected pre‑existing hypocalcemia despite supplementation is a denial trigger.

    Background

    Denosumab (Prolia®, Xgeva®) is a RANK ligand (RANKL) inhibitor used to treat conditions related to decreased bone mass and to prevent or manage skeletal complications from oncologic disease. Prolia is indicated for adults with osteoporosis and other bone-loss conditions (including postmenopausal osteoporosis, osteoporosis in men, glucocorticoid‑induced osteoporosis, and bone loss related to cancer therapies) and is subject to age and baseline bone density/FRAX requirements. Xgeva is indicated for prevention of skeletal‑related events in adults with bone metastases or multiple myeloma, treatment of unresectable giant cell tumor of bone in skeletally mature patients, and for hypercalcemia of malignancy refractory to bisphosphonates; Xgeva’s hypercalcemia indication requires an albumin‑corrected calcium > 12.5 mg/dL (3.1 mmol/L).

    Definitions

    Denosumab mechanism/class
    Drug classRANK ligand (RANKL) inhibitor
    ExamplesDenosumab marketed as Prolia and Xgeva
    Primary useTreatment of osteoporosis and prevention/treatment of oncologic bone conditions per FDA indications
    FRAX score thresholds
    DefinitionFRAX — U.S. adapted World Health Organization algorithm estimating 10-year probability of fracture
    Thresholds usedMajor osteoporotic fracture ≥20% OR hip fracture ≥3%
    Role in authorizationAccepted as baseline risk documentation alternative to T-score for Prolia